Skip to main content
Open access
ARTICLES
Published Online: 8 June 2023

Simple and Objective Evaluation Items for the Prognosis and Mortality of Delirium in Real‐World Clinical Practice: A Preliminary Retrospective Study

Publication: Psychiatric Research and Clinical Practice

Abstract

Objective

Identifying factors associated with poor outcomes in patients with delirium is important for predicting prognosis. This retrospective study developed an easy and objective cognitive function measurement scale that can predict the prognosis and mortality related to delirium.

Methods

Fifty‐five patients aged ≥65 years and diagnosed with delirium were included. Objective data regarding attention and orientation related to time and place were extracted from their medical records during the first consultation, and in total, six points were evaluated. The patients were categorized into high and low cognitive function (LCF) groups. The severity at the first visit and 1‐week post‐treatment was evaluated using the Clinical Global Impressions‐Severity scale. Outcomes (survival or death) at 6 months from the initial visit were evaluated by reviewing medical records.

Results

Although the Clinical Global Impressions‐Severity score at the first visit was not significantly different between the two groups, 1 week after treatment, it was significantly lower in the high cognitive function (HCF) group than in the LCF group. Regarding the outcome (survival or death) after 6 months, the LCF group had significantly higher mortality than the HCF group. A multivariate logistic regression analysis revealed the same result (OR = 17.049, 95% CI = 2.415–120.373, p = 0.004).

Conclusion

A simple cognitive assessment of attention and orientation may help predict unfavorable outcomes, including mortality, in patients with delirium.

Highlights

Delirium patients with low cognitive function had significantly higher mortality and poorer improvement than those with high cognitive function.
Assessing orientation and attention at the initial delirium intervention may predict improvement in delirium during hospitalization and mortality after 6 months.
Simple cognitive assessment without subjective evaluation items can be performed quickly by anyone, which may be helpful in busy clinical practices.
Delirium is a relatively common illness that occurs in approximately 11%–42% of hospitalizations and seriously affects mortality, functional outcomes, length of hospital stay, and institutional admission (1). Although many cases of delirium resolve within a few days, approximately 20% of the cases last for weeks or months (2). Therefore, identifying factors associated with poor outcomes in patients with delirium is important for predicting prognosis (3).
Previous studies have shown that severe delirium (e.g., severe cases of sleep‐wake rhythm disturbances, perceptual disturbances, delusions, cognitive impairment, and psychomotor activity) has a poor prognosis, including high mortality (4, 5). However, the general delirium rating scales (i.e., Delirium Rating Scale Revised 98 [DRS‐R] and Memorial Delirium Assessment Scale [MDAS]) used in these studies are difficult to use in a clinical setting because of administration time and prerequisite training (6). Bellelli et al. developed the 4 “A”s test, also known as the 4AT, to address the shortcomings of the existing delirium assessment tools (6). The 4AT is a tool that does not require specialized training and consists of only four components: awareness, cognitive functions, attention, and a significant change or fluctuation in the patient's mental or alertness condition. The tool has high sensitivity and specificity for predicting mortality in patients with delirium (7). A study examining the relationship between severity measured by the 4AT and prognosis showed higher mortality rates among severe cases, indicating that cognitive function may be associated with poor prognosis in patients with delirium (8).
The 4AT includes subjective items, a concern raised in previous studies, as owing to its simplicity (8), it can reduce the screening sensitivity in a busy clinical environment, such as an intensive care unit (9). Therefore, a separate tool, less susceptible to subjectivity, is necessary to evaluate the prognosis of delirium in a busy clinical setting.
Regarding objectivity, a small‐size bispectral electroencephalography (EEG) device was recently developed, with reports indicating that slower EEG activity correlates with higher delirium severity and mortality (10). However, such specialized examination and analysis equipment are not widely available in general hospitals.
In this study, we developed an easy and objective cognitive function measurement scale that could predict the prognosis and mortality related to delirium.

Methods

Participants

This retrospective study was conducted at Nihaonkai General Hospital, an acute general hospital with 630 beds and without a psychiatry ward in the Shonai region of Yamagata Prefecture, Japan. The study was conducted according to the Declaration of Helsinki, and was approved by the Institutional Review Board of Nihonkai General Hospital (approval number: 00239). Owing to the retrospective study design, the requirement for obtaining informed consent from the patients was waived.
Three hundred nine patients aged ≥65 years who met with our psychiatry consultation team between November 2020 and November 2021 were diagnosed with delirium by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (11). Two psychiatrists (YS and SK) reviewed the patients' medical records.
Our inclusion criteria required that information on orientation related to place, time, and attention, which was assessed at the first consultation, was included in the medical records. We excluded patients diagnosed with hypoactive delirium because it is known to have a poorer prognosis than the other motor subtype of delirium (12). In addition, drug‐induced delirium, alcohol withdrawal syndrome, acute cerebrovascular disease, dementia, or those who could not communicate because of sedation were also excluded to remove other types of cognitive function impairment. Patients with dementia were defined as individuals with clinically diagnosed dementia or those who underwent routine family interviews to detect dementia before hospitalization. In total, 55 patients with delirium were identified for this study (Figure 1). The primary outcome was death within 6 months after the first visit.
image
FIGURE 1. Participant selection flow chart.

Assessment of Cognitive Function

Since the purpose of this study was to identify factors associated with the prognosis of delirium quickly and objectively, we referred to the simplest of the 4AT among existing delirium assessment tools. We focused on time and place orientation and attention, which were objective evaluation items among 4AT.
The reviewing psychiatrists extracted data regarding time and place orientations and attention (aspects examined at the bedside during the first visit from 10 a.m. to 4 p.m. by the consulting psychiatry team). Only items corresponding to the subitems of the revised Hasegawa Dementia Scale (HDS‐R) (13, 14), a commonly used test for screening dementia in Japan, were evaluated. Patients were assessed for the following:
1.
Orientation
a.
Date: considered correct only if both month and day are correct
b.
Location: correct answer only if the hospital name is correct
2.
Attention
a.
Three‐digit span reverse
b.
Four‐digit span reverse (not performed if the three‐digit span reverse is incorrect)
c.
Calculation 1 (subtract 7 from 100)
d.
Calculation 2 (subtract another 7 from the answer of calculation 1; not performed if calculation 1 is incorrect)
The correct answer for each item was set at one point, and in total, six points were evaluated. The average score for the 55 participants was 2.82 ± 1.61. As such, the demarcation point for cognitive function at the first visit was set to 2/3, where a score of ≤2 was considered low cognitive function (LCF), and a score of ≥3 was considered high cognitive function (HCF). The patients were categorized into two cognitive function groups, HCF and LCF, based on the average scores.

Assessment of Severity of Delirium

The severity of delirium at the first visit and after 1 week of treatment was evaluated using Clinical Global Impressions‐Severity scale (CGI‐S; Day 0 and Day 7) and rated on the following seven‐point scale: 1 = normal, not ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients (15). The CGI‐S provides an overall clinician‐determined summary measure that considers all available information, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function (16). The CGI‐S score was determined by an independent review of the medical record by three psychiatrists (TN, TT, and RK). If there was disagreement regarding scoring, the three evaluators discussed it until they reached a consensus.

Statistical Methods and Analysis

Student's t‐test and chi‐square tests were used to compare the clinical and demographic data between the HCF and LCF groups. Some CGI‐S scores were compared using the Mann–Whitney U test. Univariate and multivariate logistic regression analyses were used to calculate the odds ratio (OR) and 95% confidence intervals (CIs) for mortality after 6 months as a function of cognitive function. The multivariable model was adjusted for age, sex, therapeutic agent (hypnotics, atypical antipsychotics, and hypnotics + atypical antipsychotics + others), and age‐adjusted Charlson Comorbidity Index as a general index of comorbidity (17). All statistical analyses were performed using SPSS version 28 for Windows (IBM, Armonk, NY, USA). A two‐sided p‐value of <0.05 was considered statistically significant.

Results

Table 1 shows the demographic and clinical data of the participants. The participants included 24 women (43.6%), averaging 6.53 (±5.34) days from admission to the first visit. No significant differences between the HCF (n = 32) and LCF (n = 23) groups were noted in the baseline characteristics (e.g., sex, age, use of a therapeutic agent, or age‐adjusted Charlson Comorbidity Index).
TABLE 1. Characteristics of the high and low cognitive function groups.
 High cognitive function (n = 32)Low cognitive function (n = 23)p‐value
Female15 (46.9%)9 (39.1%)0.60
Age, years79.13 ± 7.2081.61 ± 6.170.19
Therapeutic agents at the first visit
Atypical antipsychotics, hypnotics, etc15 (46.9%)12 (52.2%)0.83
Atypical antipsychotics only2 (6.3%)2 (8.7%) 
Hypnotics only15 (46.9%)9 (39.1%) 
Days from the onset of delirium to the first visit2.28 ± 2.344.26 ± 5.290.10
Length of hospital stay22.53 ± 11.1328.13 ± 11.490.08
Age‐adjusted Charlson Comorbidity Index6.03 ± 1.826.57 ± 2.520.37

Comparison of Severity and Outcome

CGI‐S at the first visit showed no significant difference between the LCF and HCF groups (median [range]: 4 [3–6] vs. 4.5 [3–6]; p = 0.82) (Figure 2A). One week after treatment, CGI‐S was significantly different between the LCF and HCF groups (median [range]: 3 [2–6] vs. 2 [1–5], respectively; p = 0.043) (Figure 2B). After 6 months, there were three deaths (9.4%) in the HCF group and 11 in the LCF group (p = 0.002). A multivariate logistic regression analysis revealed that the LCF group at the first visit had significantly higher mortality after 6 months (OR = 17.049, 95% CI = 2.415–120.373, p = 0.004).
image
FIGURE 2. Boxplot of CGI‐S and CGI‐I scores in low and high cognitive function groups. CGI‐S, Clinical Global Impressions‐Severity.

Discussion

Our findings revealed that the mortality rates after 6 months were 9.4% and 47.8% in the HCF and LCF groups, respectively. Multivariate analysis, adjusting for age, sex, therapeutic agents at the first visit, and type of physical illnesses, found that cognitive function at the first visit was independently associated with mortality at 6 months. In addition, the CGI‐S measured 7 days after the initial assessment was associated with a significantly poorer prognosis in the LCF group. These results show that assessing orientation and attention at the initial delirium intervention may predict improvement in delirium during hospitalization and mortality after 6 months.
A recent meta‐analysis on the components of delirium and mortality showed that altered arousal levels, attention deficit, and disorientation are associated with higher mortality (3). Furthermore, the combination of attention deficit and disorientation in older patients with delirium is a stronger predictor of in‐hospital mortality (18).
Several studies investigating the severity and prognosis of delirium used MDAS (4, 19), DRS‐R‐98 (20), and 4AT (8). MDAS and DRS‐R‐98 are difficult to apply in a busy clinical practice because of the required time and training. All the assessment tools for delirium, even the 4AT, can be difficult for untrained physicians to use to correctly assess alertness levels and acute fluctuations (8). Simple delirium assessments such as the Confusion Assessment Method (21) and Nursing Delirium Screening Scale (22) are used to assess delirium. However, they include evaluation items that may be influenced by the examiner's subjectivity. On the contrary, this study's simple and objective cognitive function evaluation using orientation and attention can be applied in a real‐world clinical setting because of its unambiguity, short administration time, and lack of additional training requirements.
Scales that rely on consultant psychiatrists are challenging to use as a shared evaluation method for the entire hospital. However, many types of medical staff, including nurses, can perform our simple cognitive assessment without consulting with a psychiatrist or having special training. The accuracy of the delirium prognosis prediction may be improved throughout the hospital by conducting this evaluation, and treatment strategies for the good and poor prognosis groups may be selected more efficiently and appropriately. For example, the group expected to make good progress would receive delirium treatment according to a predetermined protocol before consulting a psychiatrist. Similarly, the group expected to make poor progress would receive psychiatric consultation as early as possible. Hatta showed that suvorexant and ramelteon are effective in preventing delirium (23). In this study, the administration of such drugs significantly reduced subsequent delirium in patients at high risk for delirium and even in those who developed delirium before consultation. A protocol for administering such medications before psychiatric consultation may result in adequate delirium management for patients delirium, especially those who are expected to improve favorably.
This study has several limitations. First, this study was a retrospective single‐center study of a small sample of patients. Therefore, multicenter prospective studies are required to validate our results. Second, we excluded patients with dementia to rule out the effects of cognitive dysfunction related to dementia in this study. In practice, delirium with dementia cannot be ignored in clinical practice, and these results may not be able to be generalized to that condition. Third, while the simple orientation and attentional assessment used in this study can help assess the prognosis of delirium, it should be noted that it is less specific for delirium screening (6). Finally, this study targeted hyperactive delirium and excluded hypoactive delirium, although only three cases were excluded. Therefore, this could indicate that the screening protocol for hypoactive delirium in our hospital is not very effective. Further research including hypoactive delirium is needed, which is challenging to diagnose (24).
This simple cognitive assessment without subjective evaluation items can be performed quickly by anyone, which may be helpful in busy clinical practices. Larger prospective studies are needed to confirm whether orientation and attention assessment can predict the prognosis of delirium.
In conclusion, this retrospective study showed that a simple cognitive assessment of attention and orientation might predict unfavorable outcomes, including mortality, in patients with delirium.

Footnotes

We want to thank Editage (www.editage.com) for English language editing. This study has received no funding.
The authors declare no conflict of interest for this article.
The Ethical Review Committee of Nihonkai General Hospital approved this study (approval number: 00239).
The requirement for obtaining informed consent from the patients was waived because this study was retrospective design by the Ethical Review Committee of Nihonkai General Hospital (approval number: 00239).
Clinical trial registration: N/A.

REFERENCES

1.
Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in‐patients: a systematic literature review. Age Ageing. 2006;35(4):350–364. https://doi.org/10.1093/ageing/afl005
2.
Cole MG, Ciampi A, Belzile E, Zhong L. Persistent delirium in older hospital patients: a systematic review of frequency and prognosis. Age Ageing. 2009;38(1):19–26. https://doi.org/10.1093/ageing/afn253
3.
Tieges Z, Quinn T, MacKenzie L, Davis D, Muniz‐Terrera G, MacLullich AMJ, et al. Association between components of the delirium syndrome and outcomes in hospitalised adults: a systematic review and meta‐analysis. BMC Geriatr. 2021;21(1):162. https://doi.org/10.1186/s12877-021-02095-z
4.
Marcantonio E, Ta T, Duthie E, Resnick NM. Delirium severity and psychomotor types: their relationship with outcomes after hip fracture repair. J Am Geriatr Soc. 2002;50(5):850–857. https://doi.org/10.1046/j.1532-5415.2002.50210.x
5.
Yamanashi T, Iwata M, Crutchley KJ, Sullivan EJ, Malicoat JR, Anderson ZM, et al. New cutoff scores for delirium screening tools to predict patient mortality. J Am Geriatr Soc. 2021;69(1):140–147. https://doi.org/10.1111/jgs.16815
6.
Bellelli G, Morandi A, Davis DH, Mazzola P, Turco R, Gentile S, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014;43(4):496–502. https://doi.org/10.1093/ageing/afu021
7.
Hasegawa T, Seo T, Kubota Y, Sudo T, Yokota K, Miyazaki N, et al. Reliability and validity of the Japanese version of the 4A's Test for delirium screening in the elderly patient. Asian J Psychiatr. 2022;67:102918. https://doi.org/10.1016/j.ajp.2021.102918
8.
Evensen S, Hylen Ranhoff A, Lydersen S, Saltvedt I. The delirium screening tool 4AT in routine clinical practice: prediction of mortality, sensitivity and specificity. Eur Geriatr Med. 2021;12(4):793–800. https://doi.org/10.1007/s41999-021-00489-1
9.
van Eijk MM, van den Boogaard M, van Marum RJ, Benner P, Eikelenboom P, Honing ML, et al. Routine use of the confusion assessment method for the intensive care unit: a multicenter study. Am J Respir Crit Care Med. 2011;184(3):340–344. https://doi.org/10.1164/rccm.201101-0065oc
10.
Yamanashi T, Crutchley KJ, Wahba NE, Sullivan EJ, Comp KR, Kajitani M, et al. Evaluation of point‐of‐care thumb‐size bispectral electroencephalography device to quantify delirium severity and predict mortality. Br J Psychiatry. 2021;2(6):1–8. https://doi.org/10.1192/bjp.2021.101
11.
American Psychiatric Association . Diagnostic and statistical manual for mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.
12.
Meagher DJ, Leonard M, Donnelly S, Conroy M, Adamis D, Trzepacz PT. A longitudinal study of motor subtypes in delirium: relationship with other phenomenology, etiology, medication exposure and prognosis. J Psychosom Res. 2011;71(6):395–403. https://doi.org/10.1016/j.jpsychores.2011.06.001
13.
Katoh S, Shimogaki H, Onodera A, Ueda H, Oikawa K, Ikeda K, et al. Development of the revised version of Hasegawa’s Dementia Scale (HDS‐R) (in Japanese). RounenSeishin Igaku Zasshi (Jpn J Geriat Psychiat). 1991;2:1339–1347.
14.
Jeong JW, Kim KW, Lee DY, Lee S, Park J, Choi E, et al. A normative study of the Revised Hasegawa Dementia Scale: comparison of demographic influences between the Revised Hasegawa Dementia Scale and the Mini‐Mental Status Examination. Dement Geriatr Cogn Disord. 2007;24(4):288–293. https://doi.org/10.1159/000107592
15.
Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville: US Department of Health Education, and Welfare Public Health Service Alcohol. Drug Abuse, and Mental Health Administration; 1976.
16.
Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37.
17.
Maezawa Y, Aoyama T, Kano K, Tamagawa H, Numata M, Hara K, et al. Impact of the age‐adjusted Charlson Comorbidity Index on the short‐ and long‐term outcomes of patients undergoing curative gastrectomy for gastric cancer. J Cancer. 2019;10(22):5527–5535. https://doi.org/10.7150/jca.35465
18.
Bellelli G, Nobili A, Annoni G, Morandi A, Djade C, Meagher D, et al. Under‐detection of delirium and impact of neurocognitive deficits on in‐hospital mortality among acute geriatric and medical wards. Eur J Intern Med. 2015;26(9):696–704. https://doi.org/10.1016/j.ejim.2015.08.006
19.
Mercadante S, Adile C, Ferrera P, Cortegiani A, Casuccio A. Delirium assessed by Memorial Delirium Assessment Scale in advanced cancer patients admitted to an acute palliative/supportive care unit. Curr Med Res Opin. 2017;33(7):1303–1308. https://doi.org/10.1080/03007995.2017.1315332
20.
Pal S, Sharma N, Singh SM, Kumar S, Pannu AK. A prospective cohort study on predictors of mortality of delirium in an emergency observational unit. QJM. 2021;114(4):246–251. https://doi.org/10.1093/qjmed/hcaa183
21.
Inouye SK, Kosar CM, Tommet D, Schmitt EM, Puelle MR, Saczynski JS, et al. The CAM‐S: development and validation of a new scoring system for delirium severity in 2 cohorts. Ann Intern Med. 2014;160(8):526–533. https://doi.org/10.7326/m13-1927
22.
Gaudreau JD, Gagnon P, Harel F, Tremblay A, Roy MA. Fast, systematic, and continuous delirium assessment in hospitalized patients: the Nursing Delirium Screening Scale. J Pain Symptom Manag. 2005;29(4):368–375. https://doi.org/10.1016/j.jpainsymman.2004.07.009
23.
Hatta K, Kishi Y, Wada K, Takeuchi T, Hashimoto N, Suda K, et al. Real‐world effectiveness of ramelteon and suvorexant for delirium prevention in 948 patients with delirium risk factors. J Clin Psychiatry. 2019;81(1):19m12865. https://doi.org/10.4088/jcp.19m12865
24.
van Velthuijsen EL, Zwakhalen SMG, Mulder WJ, Verhey FR, Kempen GI. Detection and management of hyperactive and hypoactive delirium in older patients during hospitalisation: a retrospective cohort study evaluating daily practice. Int J Geriatr Psychiatr. 2018;33(11):1521–1529. https://doi.org/10.1002/gps.4690

Information & Authors

Information

Published In

Go to Psychiatric Research and Clinical Practice
Psychiatric Research and Clinical Practice
Pages: 126 - 130

History

Received: 31 January 2023
Revision received: 15 May 2023
Accepted: 17 May 2023
Published online: 8 June 2023
Published in print: Winter 2023

Authors

Details

Yuzuru Shibuya, M.D., Ph.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)
Ryota Kobayashi, M.D., Ph.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)
Takuma Numazawa, M.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)
Toyoki Toyoshima, M.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)
Hiroshi Hayashi, M.D., Ph.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)
Toshimasa Sone, O.T.R., Ph.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)
Daichi Morioka, M.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)
Akihito Suzuki, M.D., Ph.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)
Shinobu Kawakatsu, M.D., Ph.D.
Department of Psychiatry, Nihonkai General Hospital, Sakata, Japan (Y. Shibuya, T. Numazawa, T. Toyoshima, S. Kawakatsu); Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan (R. Kobayashi, D. Morioka, A. Suzuki); Department of Occupational Therapy, Fukushima Medical University School of Health Sciences, Fukushima, Japan (H. Hayashi, T. Sone); Department of Neuropsychiatry, Aizu Medical Centre, Fukushima Medical University, Aizuwakamatsu, Japan (S. Kawakatsu)

Notes

Send correspondence to Dr. Shibuya
([email protected])

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share